About SubjectWell
SubjectWell is a company based in Austin (United States) founded in 2012 was acquired by WindRose Health Investors in April 2024. SubjectWell has raised $46.8 million across 3 funding rounds from investors including Asset Management Ventures, Bertelsmann Investments and Windham Capital Partners. SubjectWell has completed 2 acquisitions, including PatientCentra and Trials24. SubjectWell offers products and services including SubjectWell+ Platform, Study Connect, Direct Connect, Brand Connect, and Virtual Waiting Room. SubjectWell operates in a competitive market with competitors including Evidation, myTomorrows, Antidote, Dyania Health and Clara Health, among others.
- Headquarter Austin, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$46.8 M (USD)
in 3 rounds
-
Latest Funding Round
$35 M (USD), Series B
Oct 20, 2022
-
Investors
Asset Management Ventures
& 5 more
-
Employee Count
Not available
-
Investments & Acquisitions
PatientCentra
& 1 more
-
Acquired by
WindRose Health Investors
(Apr 30, 2024)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of SubjectWell
SubjectWell offers a comprehensive portfolio of products and services, including SubjectWell+ Platform, Study Connect, Direct Connect, Brand Connect, and Virtual Waiting Room.
Technology for managing clinical trial recruitment and site enablement.
Connects patients to clinical studies efficiently.
Facilitates direct patient enrollment in trials.
Supports marketing and patient engagement for brands.
Keeps patients engaged before trial participation.
People of SubjectWell
Unlock access to complete
Unlock access to complete
Funding Insights of SubjectWell
SubjectWell has successfully raised a total of $46.8M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $35 million completed in October 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in SubjectWell
SubjectWell has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Asset Management Ventures, Bertelsmann Investments and Windham Capital Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage US companies are invested in by Asset Management Ventures.
|
Locked | Locked | Locked | |
|
Venture capital fund investing in multiple sectors
|
Locked | Locked | Locked | |
|
Venture capital funding is provided to early-stage startups.
|
Locked | Locked | Locked |
Investor details for SubjectWell
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by SubjectWell
SubjectWell has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include PatientCentra and Trials24.
Investment portfolio details for SubjectWell
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Patient recruitment and engagement platform for clinical trials is provided.
|
Locked | Locked | 2017 | Locked | |
|
Customized clinical trial patient recruitment solutions are provided globally.
|
Locked | Locked | 2013 | Locked |
Complete acquisition details for SubjectWell
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - SubjectWell
Detailed financials for SubjectWell
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Subjectwell Comparisons
Peer comparison for SubjectWell
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of SubjectWell
SubjectWell operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Evidation, myTomorrows, Antidote, Dyania Health and Clara Health, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Real-world health data is provided for research and decisions.
|
|
| Locked | Locked | Locked |
Platform provides access to drugs in development to patients and physicians
|
|
| Locked | Locked | Locked |
Provider of search engine tool for patients to explore, understand and access clinical trials.
|
|
| Locked | Locked | Locked |
Patients for clinical trials are identified through a dedicated platform.
|
|
| Locked | Locked | Locked |
Clinical trials are matched to patients via an online platform.
|
Detailed competitors of SubjectWell
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Subjectwell
Complete news archive for SubjectWell
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about SubjectWell
SubjectWell was founded in 2012 and raised its 1st funding round 6 years after it was founded.
SubjectWell is headquartered in Austin, United States. It is registered at Austin, Texas, United States.
Fred Martin is the current CEO of SubjectWell.
SubjectWell is a funded company, having raised a total of $46.8M across 3 funding rounds to date.
SubjectWell was founded in 2012 in Austin, United States, within the health technology sector. A platform is operated to identify and engage patients interested in clinical trials, facilitating introductions and alerts to relevant opportunities. Quality referrals are ensured through prescreening processes, supporting recruitment efforts for trial sponsors across the United States.
SubjectWell's top competitors include Evidation, myTomorrows and Dyania Health.
SubjectWell offers SubjectWell+ Platform, Study Connect, Direct Connect, Brand Connect, and Virtual Waiting Room.
SubjectWell has made 2 acquisitions, including PatientCentra, and Trials24.
SubjectWell has 6 investors. Key investors include Asset Management Ventures, Bertelsmann Investments, Windham Capital Partners, Geekdom Fund, and Healthy Ventures.